Insilico Medicine (03696.HK), a China-based biotechnology company, announced on Tuesday that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co, Ltd (06938.HK), a China-based, clinical-stage company in oligonucleotide therapeutics.

Building on the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties says that they will further deepen the existing experimental service cooperation, combining the end-to-end R&D capabilities of Insilico's proprietary Pharma.AI platform with Ribo's expertise in oligonucleotide therapeutics development, aiming for comprehensive efficiency boost in the oligonucleotide drug R&D cycle.

In the field of oligonucleotide therapeutics development, AI is already playing a considerable role in processes including target screening and identification, and data modelling and simulation. Through evaluation of target clinical effects in large patient databases, AI supports prediction of clinical efficacy and safety, improving the efficiency and certainty of clinical research. The cooperation will combine Insilico's AI system covering the entire drug development process with Ribo's three-dimensionally integrated oligonucleotide therapeutics development platform to enhance efficiency at various research stages and accelerate the R&D process of innovative oligonucleotide therapeutics.